Abu Dhabi to advance neurodegenerative disease patient care in the Emirate

A centre of excellence for the condition will be established featuring therapeutic innovations.

Abu Dhabi’s Department of Health (DoH) is set to enhance patient care for neurodegenerative diseases through a Memorandum of Understanding (MoU) with Eli Lilly Suisse S.A.

The agreement will witness the establishment of a centre of excellence in neurodegenerative disease care featuring therapeutic innovations, diagnostic technologies and the latest patient monitoring and follow-up protocols.

Moreover, the collaboration aims to leverage existing and emerging treatments and care technologies within the Emirate.

“Through refining diagnostic processes and implementing state-of-the-art early detection, this partnership will help in advancing the management of neurodegenerative disease in a proactive way,” Asma Al Mannaei, Executive Director of the Research and Innovation Center at the DoH – Abu Dhabi said.

“It will facilitate the much-needed transition from healthcare to health, a departure from the traditional reactive model of treating illnesses to a proactive focus on promoting holistic health and wellness,” Al Mannaei added.